This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Remer, C F Articles by Wallace, D J Search for Related Content PubMed PubMed Citation Articles by Remer, C F Articles by Wallace, D J Social Bookmarking                   What's this?

Benefyts of lefiunomide in systemic lupus erythematosus: a pilot observational study

Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA

M H Weisman

Division of Rheumatology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Room B-122, Los Angeles, CA 90048, USA; weisman{at}cshs.org

D J Wallace

Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA

The objective of this study was to retrospectively explore the safety and efficacy of leflunomide (LEF) in outpatients with systemic lupus erythematosus (SLE).

Eighteen SLE females received LEF, open label, 100 mgday loading dose for 3 days followed by 20 mg per day. Patients were evaluated for safety and efficacy after 2—3 months of therapy.

The mean age was 42.6 y and mean disease duration 7.9 y. ACR criteria were met by 1518. Four patients stopped LEF during the observation period. Ten of 14 LEF-treated patients had subjective improvement with 914 patients achieving lower SLEDAI scores. The mean SLEDAI decreased by 2.1 (P=0.005) and the mean ESR decreased by 9 mm h(P=0.02). Prednisone dosages could be reduced in 25 subjects without a flare. No organ-threatening or life-threatening side effects were seen in our patients. Diarrhea occurred in seven patients (two stopped LEF), rash occurred in one patient (stopped LEF), one patient stopped LEF for reasons not related to therapy. Blood pressure was unchanged.

Leflunomide was efficacious and safe in this cohort of SLE patients after 2—3 months of therapy. Placebo-controlled trials of longer duration are indicated.

Key Words: lefiunomide • observational study • clinical study • DMARD • SLE

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Wang, T. Cui, F. Hou, Z. Ni, X. Chen, F. Lu, F. Xu, X. Yu, F. Zhang, X. Zhao, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study Lupus, July 1, 2008; 17(7): 638 - 644. [Abstract] [PDF]

				J. Martin, J. Ricart, J Alcacer, N Rausell, and G Arana Adalimumab-induced lupus erythematosus Lupus, July 1, 2008; 17(7): 676 - 678. [Abstract] [PDF]

				M. Petri Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii61 - iii64. [Abstract] [Full Text] [PDF]

				L-S Tam, E K Li, C-K Wong, C W. Lam, and C-C Szeto Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus Lupus, August 1, 2004; 13(8): 601 - 604. [Abstract] [PDF]